Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
Enavate Sciences entities filed Amendment No. 3 to report that they beneficially own 2,495,562 shares of CAMP4 Therapeutics common stock, representing 4.8% of the class based on 51,919,321 shares outstanding as of March 4, 2026. Everest LP holds the shares directly, and Enavate Sciences GP, LLC, as general partner, shares voting and investment power. The reporting persons state they ceased to be beneficial owners of more than five percent of the common stock on March 9, 2026. In the prior sixty days, Everest LP sold multiple blocks of shares in open-market trades, including 91,699 shares on March 9, 2026 at a weighted average price of $6.69 per share and 99,639 shares on March 10, 2026 at a weighted average price of $5.83 per share.
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on RNA-targeting antisense oligonucleotides that upregulate gene expression for genetic diseases. Its proprietary RAP Platform maps regulatory RNAs to design ASOs that increase protein production in a gene-specific way, with an emphasis on central nervous system disorders.
The lead candidate, CMP-002, targets SYNGAP1-related developmental and epileptic encephalopathy. In preclinical models, CMP-002 restored SYNGAP protein toward normal levels, improved behavioral deficits in haploinsufficient mice, and increased SYNGAP protein across disease-relevant brain regions in cynomolgus monkeys. GLP toxicology studies are underway to support a planned global Phase 1/2 trial in SYNGAP1 as early as the second half of 2026.
CAMP4’s second candidate, CMP-001, aims to treat urea cycle disorders by amplifying CPS1 expression. A Phase 1 trial in healthy volunteers showed a favorable safety and pharmacokinetic profile, but further internal investment has been paused while the company seeks partners. In December 2025, CAMP4 signed a research, collaboration and license agreement with GSK, receiving a $17.5 million upfront payment and eligibility for up to $440 million in milestones plus tiered royalties on future net sales.
The company highlights extensive risk factors, including recurring losses, the need for substantial additional capital, heavy reliance on CMP-002, manufacturing and regulatory dependencies, competition from other gene-modulating and antisense companies, potential challenges maintaining Nasdaq listing standards, and significant stock price volatility. As of June 30, 2025, non-affiliate market value of common stock was approximately $14.6 million, and as of March 4, 2026, there were 51,919,321 common shares outstanding.
CAMP4 Therapeutics reported full-year 2025 results and highlighted major strategic and financing milestones. Cash and cash equivalents rose to $109.5 million as of December 31, 2025, up from $64.0 million a year earlier, and the company believes this will fund planned activities into 2028.
Research and collaboration revenue increased to $3.5 million, while R&D expenses were $38.2 million and G&A expenses were $17.4 million. Net loss widened to $80.4 million, mainly due to a $29.8 million non-cash loss from a derivative tranche liability tied to a private placement. CAMP4 entered a strategic collaboration with GSK, receiving a $17.5 million upfront payment and potential milestones up to $440 million plus tiered royalties, and completed equity financings totaling $80 million in gross proceeds with potential for an additional $50 million. The company advanced its lead SYNGAP1 program CMP-002 toward a planned global Phase 1/2 trial as early as the second half of 2026 and paused further internal investment in CMP-001 while exploring partnerships.
Camp4 Therapeutics Corp received an amended Schedule 13G/A from investment entities affiliated with Vivo Opportunity, reporting significant passive ownership stakes in its common stock. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each beneficially own 3,856,991 shares, representing 7.4% of Camp4’s common stock based on 51,880,185 shares outstanding as of December 18, 2025. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each beneficially own 389,577 shares, or 0.8% of the same share base. The filing states that these securities are not held for the purpose of changing or influencing control of Camp4, but rather as passive investments.
FMR LLC and Abigail P. Johnson report a significant ownership stake in CAMP4 Therapeutics Corporation. As of the event date, they beneficially own 4,918,243 shares of CAMP4 common stock, representing 9.5% of the outstanding class.
FMR LLC has sole voting power over 4,916,914 shares and sole dispositive power over 4,918,243 shares, while Abigail P. Johnson is reported with sole dispositive power over the same 4,918,243 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
CAMP4 Therapeutics Corporation reported that it has updated its corporate investor presentation as of January 2026. The company uses this presentation to provide the investment community with updates and summaries of its business. The refreshed materials are available in the Investors section of its website and have also been furnished as Exhibit 99.1 to this report under Regulation FD.
The company notes that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
Janus Henderson Group plc filed a Schedule 13G reporting beneficial ownership of 6,307,636 shares of CAMP4 Therapeutics Corp common stock, representing 12.2% of the class. The filing states that Janus Henderson Investors US LLC may be deemed the beneficial owner of these shares and also holds 1,241,382 pre-funded warrants that cannot be exercised if doing so would push ownership above 9.99%. All voting and dispositive power over the reported shares is shared, with no sole voting or dispositive power. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of CAMP4.
CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC for a public offering of 5,000,000 shares of its common stock at $6.00 per share. All shares are being sold by the company, which estimates net proceeds of approximately $28.0 million after underwriting discounts, commissions, and expenses.
The shares are being issued under an effective Form S-3 shelf registration statement, with a related prospectus supplement filed on December 18, 2025. Closing of the offering is expected on or about December 19, 2025, subject to customary conditions. The company, its executive officers, directors, and certain stockholders agreed to a 60-day lock-up, while sales under the company’s at-the-market program may resume after 30 days from the underwriting agreement date.
CAMP4 Therapeutics Corporation is offering 5,000,000 shares of its common stock at $6.00 per share, a primary offering that will provide approximately $28.0 million in net proceeds. The shares trade on the Nasdaq Global Market under the symbol “CAMP” and are expected to be delivered on or about December 19, 2025. After the deal, shares outstanding are expected to increase to 51,880,185, meaning existing holders are diluted but the company adds cash it plans to use mainly to advance its RNA-targeting drug pipeline and for general corporate purposes. New investors will see immediate dilution, as the as adjusted net tangible book value is estimated at $1.67 per share compared with the $6.00 purchase price.
CAMP4 Therapeutics Corporation entered into a major Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited to develop antisense oligonucleotide therapeutics for neurodegenerative and kidney disease targets. CAMP4 will use its regulatory RNA mapping and ASO discovery platform to identify and deliver lead ASO series for multiple collaboration targets, after which GSK assumes sole global responsibility for development, regulatory work, manufacturing, and commercialization.
Under the agreement, CAMP4 receives a one-time, non-refundable upfront payment of $17.5 million and is eligible for up to $440 million in development and commercial milestone payments if specified criteria are met, plus tiered royalties from low- to mid-single digits on annual net sales. The agreement includes customary governance, diligence, intellectual property, confidentiality, and indemnification provisions and can be terminated by GSK for convenience or by either party under specified circumstances.